CCO Treatment Updates
Management of Depression and HCV: Novel Data, Best Practices, and Case Challenges
Clinical Data and Best Practices for Managing Depression in HCV-Infected Patients Treated With Peginterferon and Ribavirin |
Module 1 of 2 |
|
|
|
Martin Schaefer, MD, highlights management strategies for patients with hepatitis C virus infection and depression, highlighting new studies from the past year
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the risk factors for and incidence of depression during interferon-based treatment for HCV infection
- Discuss management strategies for depression in hepatitis C patients, including pretreatment assessment, prevention, and treatment
- Recount the effects of HCV infection and treatment on cognition, sleep patterns, and mood
- Describe the management of psychiatric disorders in hepatitis C patients with concurrent drug addiction
Abstract
|
Answering the Questions: Depression Related to HCV and Its Treatment |
Module 2 of 2 |
  
- Alfredo Alberti, MD
- Lucia Gallego, MD
- Michael R. Kraus, MD, PhD
|
 |
|
|
Alfredo Alberti, MD; Lucia Gallego, MD; Michael R. Kraus, MD, PhD; and Vicente Soriano, MD, PhD, provide practical answers to frequently asked questions about diagnosing and managing depression before and during HCV treatment.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize data regarding risk of depression development and suicidal ideation in HCV-infected patients and those receiving HCV therapy
- Explain practical strategies for diagnosing and managing patients with depression receiving HCV therapy, including management of patients with comorbidities, and the use of a multidisciplinary team
- Describe the available treatments for depression in HCV patients, their dosing schedules, measures of efficacy, and potential adverse effects
- Discuss the balance of optimal treatment duration with HCV therapy and depression management during HCV treatment
- Recount other psychiatric adverse effects during HCV therapy and how they should be screened for, diagnosed, and managed
Abstract
|
Slideset Modules
Clinical Data and Best Practices for Managing Depression in HCV-Infected Patients Treated With Peginterferon and Ribavirin
|
|
|
In this slideset module, Martin Schaefer, MD, discusses the relationships among depression, hepatitis C virus, and treatment; management strategies for depression; the effects of hepatitis C virus on cognitive function; and management of psychiatric disorders in the setting of drug addiction.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the risk factors for and frequency of depression during interferon-based treatment for HCV infection
- Discuss management strategies for depression in hepatitis C patients, including pretreatment assessment, prevention, and treatment
- Recount the effects of HCV infection and treatment on cognition, sleep patterns, and mood
- Describe the management of psychiatric disorders in hepatitis C patients with concurrent drug addiction
|
Clinical Data and Best Practices for Managing Depression in HCV-Infected Patients Treated With Peginterferon and Ribavirin
 |
|
Martin Schaefer, MD, highlights management strategies for patients with hepatitis C virus infection and depression, highlighting new studies from the past year.
Format: Microsoft PowerPoint (.ppt) |
File size: 745 KB
| Date posted: 8/5/2008
|
Answering the Questions: Depression Related to HCV and Its Treatment
- Michael R. Kraus, MD, PhD
|
|
|
In this slideset module, Michael R. Kraus, MD, PhD, addresses the most relevant questions pertaining to the clinical management of depressive symptoms in HCV-infected patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize data regarding risk of depression development and suicidal ideation in HCV-infected patients and those receiving HCV therapy
- Explain practical strategies for diagnosing and managing patients with depression receiving HCV therapy, including management of patients with comorbidities, and the use of a multidisciplinary team
- Describe the available treatments for depression in HCV patients, their dosing schedules, measures of efficacy, and potential adverse effects
- Discuss the balance of optimal treatment duration with HCV therapy and depression management during HCV treatment
- Recount other psychiatric adverse effects during HCV therapy, and how they should be screened for, diagnosed, and managed
|
Answering the Questions: Depression Related to HCV and Its Treatment
 |
|
Michael R. Kraus, MD, PhD, provides practical answers to frequently asked questions about diagnosing and managing depression before and during HCV treatment.
Format: Microsoft PowerPoint (.ppt) |
File size: 958 KB
| Date posted: 10/9/2008
|
Interactive Case Challenges
Management of a 43 Year-Old HCV-Infected, Treatment-Naive Female With a History of Major Depression
|
|
|
Join Charles L. Raison, MD, in choosing the optimal treatment strategies for a woman with recently diagnosed hepatitis C virus infection and a history of major depression.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize procedures for screening hepatitis C patients before HCV therapy
- Discuss the prophylactic use of antidepressants in patients facing HCV therapy
- Describe strategies for evaluating and managing fatigue in patients with depressive symptoms during HCV therapy
|
Management of a Patient Who Develops Psychiatric Adverse Events While Receiving Peginterferon Therapy for HCV
|
|
|
Mark S. Sulkowski, MD, discusses factors to consider when psychiatric disorders develop in patients treated for chronic hepatitis C.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss when prophylactic antidepressants should be used in patients requiring HCV therapy
- Articulate how the symptoms of depression differ from those of mania
- Recall strategies to discontinue mood therapy when HCV therapy is no longer indicated
|
Management of Emergent Depression and Suicidal Ideation During HCV Therapy
|
|
|
Join Alfredo Alberti, MD, in choosing the optimal treatment strategies for a woman who develops depressive symptoms during HCV therapy, despite the absence of symptoms at treatment baseline.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the incidence of and strategies for monitoring depression during interferon-based HCV antiviral therapy
- Describe strategies for managing depression that emerges during HCV therapy
- Articulate how the shortening of treatment can be used in genotype 2/3 HCV–infected patients who develop depressive symptoms during therapy
- Recall the incidence and management strategies for the development of suicidal ideation during HCV therapy
|
Expert Viewpoints
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
Have a question on the management of depression and HCV?
|